Rituximab and Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients With Recurrent Primary CNS Lymphoma

DISEASE CHARACTERISTICS: Histologically confirmed non-Hodgkin's lymphoma (NHL) Recurrent disease Isolated CNS relapse of systemic NHL allowed Primary CNS lymphoma Measurable gadolinium-enhancing lesion on MRI of the brain No impaired bone marrow reserve No hypocellular bone marrow No marked reduction in bone marrow precursors of one or more cell lines (granulocytic, megakaryocytic, erythroid) No pleural effusion No chronic lymphocytic leukemia No AIDS-related lymphoma PATIENT CHARACTERISTICS: Age Adult Performance status Not specified Life expectancy Not specified Hematopoietic Platelet count > 100,000/mm^3 Absolute neutrophil count ≥ 1,500/mm^3 Hepatic Bilirubin ≤ 2.0 mg/dL Renal Creatinine ≤ 2.0 mg/dL Other HIV negative No serious nonmalignant disease that would preclude study participation No infection No anti-murine antibody reactivity* No human anti-mouse antibodies Not pregnant Negative pregnancy test NOTE: *Results must be available prior to study entry for patients who received prior murine antibodies or proteins, other than rituximab PRIOR CONCURRENT THERAPY: Biologic therapy See Radiotherapy No prior stem cell transplantation No prior myeloablative therapies with autologous bone marrow transplantation or peripheral blood stem cell rescue No prior failed stem cell collection More than 2 weeks since prior filgrastim (G-CSF) or sargramostim (GM-CSF) Chemotherapy No more than 1 prior chemotherapy regimen Endocrine therapy Not specified Radiotherapy No prior radioimmunotherapy No prior whole-brain radiotherapy No prior external beam radiotherapy (involved field or regional) to > 25% of active bone marrow Surgery More than 4 weeks since prior major surgery except diagnostic surgery